LCM Capital Management Inc Acquires 25,100 Shares of Amarin Co. plc (NASDAQ:AMRN)

LCM Capital Management Inc grew its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 3.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 838,259 shares of the biopharmaceutical company’s stock after buying an additional 25,100 shares during the quarter. LCM Capital Management Inc owned 0.20% of Amarin worth $407,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Algert Global LLC bought a new position in Amarin during the 2nd quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 29,992 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Amarin by 8.8% in the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock worth $816,000 after purchasing an additional 104,939 shares during the last quarter. Arkfeld Wealth Strategies L.L.C. increased its stake in shares of Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 20,000 shares during the period. Finally, Kornitzer Capital Management Inc. KS raised its holdings in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 42,700 shares during the last quarter. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Amarin from a “hold” rating to a “sell” rating in a research report on Friday, January 24th.

Amarin Price Performance

AMRN opened at $0.57 on Thursday. Amarin Co. plc has a one year low of $0.43 and a one year high of $1.36. The business has a 50 day simple moving average of $0.52 and a two-hundred day simple moving average of $0.58. The firm has a market capitalization of $233.06 million, a price-to-earnings ratio of -6.31 and a beta of 1.83.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.